Avalere Health’s Post

“Being empathetic is also crucial for MRX, so we can go beyond a superficial understanding of people's needs and motivations.” Meet Karuna Banerjee, a rising star at the intersection of behavioral science and pharmaceutical innovation. Her unique approach is reshaping how we understand and communicate complex healthcare concepts. 🔍 Explore how Karuna is revolutionizing healthcare education and research! → https://hubs.ly/Q02JX-Pt0 #FutureList #HealthcareResearch #HealthResearch

Have you checked our latest publication on measuring and valuing the social impact of medicines? The VBA Health Cluster: Social Impact of Innovative Medicine is designed to assess the impact of innovative medicines-based health interventions and pharmaceutical activities. To measure social impact, this document introduces a methodology grounded in the initial approach as outlined by WifOR Institute and Novartis for measuring and valuing the social impact of medicines, which focuses on the social and economic perspective. Download our paper here: https://lnkd.in/dphbMHJk. #ValueBalancingAlliance #WifOR #Novartis #HealthCluster #SocialImpact

Kearny states: “Considering the clear potential to dramatically reduce the ~$300 billion annual health system spend on obesity-related conditions in the US, many see GLP-1s as the closest thing medicine has to a silver bullet for a host of costly diseases.” Learn how GLP-1s will impact the medical and pharmaceutical world in the new Kearny research: https://sie.ag/6K8nwo

A study by the USC Schaeffer Center for Health Policy & Economics and USC Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences reveals that while 19% of hospitals offer medical payment products (MPPs), only 8.5% promote interest-bearing options, predominantly having high uncompensated care rates. This research, published in JAMA Health Forum, highlights the need for regulators to consider the financial conditions of hospitals using MPPs before implementing new policies. Read more on the study here: https://lnkd.in/g6Xpwcxr

Personalized medicine, clinical chemistry, or even criminology: Diagnostics is becoming increasingly important in modern medicine. The biggest challenge? Expertise that goes far beyond filling and closing. High-tech solutions are needed. That’s why Optima specializes in the development of turnkey solutions and takes central responsibility with multiple systems from one source. “Our diagnostic customers benefit from the experience and expertise we have gained over many years of providing turnkey solutions to the pharmaceutical industry. This ensures a strong and well-established technical foundation for such tasks," says Christian Müller, Director Sales Diagnostic Global at Optima Pharma. Read the whole expert interview in the latest issue of o-com diagnostic, Page 8 - 13 ▶️ https://lnkd.in/eRWNDUDC #optima #wecareforpeople #pharma #diagnostic #medicine #turnkey

47% of attendees from our recent webinar believe Pharma should focus on a partner strategy for digital health solutions in drug delivery devices. Hear from our panelists’ thoughts on when a partner strategy is necessary, where are Pharma’s own strengths, and where Pharma should direct their efforts. What are your thoughts? Comment below. Watch our on-demand webinar "From Digital Health Alchemy to Chemistry" now 👉 https://hubs.ly/Q02BGvhg0 #DigitalHealth #Pharma

Different doctor markets, even within the same geographical region, can have vastly different structures. Some of these differences are relatively obvious, while others can be more nuanced. Across the board, however, they require tailored approaches. Pharma marketers need to consider this when planning their campaigns. Read more here https://lnkd.in/eG26civ6 #pharmamarketing #pharma #doctorinsights #HCPs #doctor #health

Really interesting chart!!

It’s a wrap! ✅ 3 Days at PSI: Statisticians in the Pharmaceutical Industry congress full of insights 💡, sharings 🙋♂️and connections 🤝 Among others: - Bayesian Methods for borrowing information 📚 - Innovation=invention x commercialization (make it done 💪🏻) - Advancement in health technology: challenges & opportunities - Estimands #PSI#Statistics#congress#amsterdam#collegues

Market Access in Life Sciences: Real World Evidence Takes Center Stage in 2023 Real World Evidence (RWE) was the top priority in the market access landscape for the life sciences sector in 2023, followed by Artificial Engagement and Pricing. Health Technology Assessment (HTA) and Value Assessment were also considered important. Other areas of interest included Health Data Management, Patient Engagement, and Public Health. The 'Other' category highlighted emerging trends and showcased the adaptability of the market access landscape. Overall, the industry is evolving to meet the challenges of the healthcare environment. For more details please click the link! https://lnkd.in/dgbfEUmY #marketaccess #reimbursement #pricing #hta #heor #healtheconomics #medicaldevices #pharmaceutical